Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Processa Pharmaceuticals ( (PCSA) ).
On April 30, 2026, Processa Pharmaceuticals approved a planned transition toward retirement for Dr. Sian Bigora, its Chief Development and Regulatory Officer. Effective May 1, 2026, she moved from a full-time executive officer role to a part-time employee position while retaining her title and continuing to provide services in a reduced capacity.
As part of the change, Dr. Bigora ceased to be designated as an executive officer under Section 16 of the Securities Exchange Act of 1934, and her existing employment agreement was replaced with a new part-time arrangement. She remains entitled to previously granted equity awards and eligible for any previously awarded bonus compensation, signaling continuity in her long-term incentives despite the reduction in her operational role.
The most recent analyst rating on (PCSA) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Processa Pharmaceuticals stock, see the PCSA Stock Forecast page.
Spark’s Take on PCSA Stock
According to Spark, TipRanks’ AI Analyst, PCSA is a Neutral.
The score is held down primarily by weak financial fundamentals (no revenue, continued losses, and ongoing cash burn) and a negative corporate event impacting a key licensing path. Technical indicators provide some near-term support, but longer-term trend levels remain unfavorable, and valuation is not supportive given the company is still loss-making with no dividend.
To see Spark’s full report on PCSA stock, click here.
More about Processa Pharmaceuticals
Processa Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing drug candidates through regulatory pathways in the U.S. and other markets. The company concentrates on advancing its clinical and regulatory programs under the oversight of specialized leadership positions such as its Chief Development and Regulatory Officer.
Average Trading Volume: 56,415
Technical Sentiment Signal: Strong Sell
Current Market Cap: $7.05M
For a thorough assessment of PCSA stock, go to TipRanks’ Stock Analysis page.